Leqvio Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of hyperlipidemia, advancements in rna interference technology, expansion of cardiovascular specialty clinics, growing awareness of ldl cholesterol management, improved injectable drug delivery systems.

The growth in the forecast period can be attributed to increasing adoption of novel rna therapeutics, rising focus on cardiovascular risk reduction, expansion of long-interval dosing therapies, growing investments in cardiometabolic research, increasing demand for durable lipid-lowering solutions. Major trends in the forecast period include increasing adoption of sirna-based lipid-lowering therapies, rising demand for long-acting cardiovascular treatments, growing focus on preventive cardiology solutions, expansion of advanced rna manufacturing technologies, enhanced emphasis on patient adherence optimization.

The growing geriatric population is expected to drive the demand for Leqvio in the future. The geriatric population consists of individuals aged 65 and above. Thanks to advancements in healthcare and medical technology, life expectancy has significantly increased, contributing to the growth of the elderly demographic. Leqvio helps lower LDL cholesterol, making medication management easier for older adults. Its long-lasting effects reduce cardiovascular risks, which improves health outcomes in this population. For instance, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, projected that the number of Americans aged 65 and older would increase from 58 million in 2022 to 82 million by 2050, a 47% rise. This age group’s share of the overall population is also expected to grow from 17% to 23% during the same period. As a result, the growing geriatric population is driving the expansion of the Leqvio market.

The rising incidence of cardiovascular diseases is expected to drive the growth of the Leqvio market in the coming years. Cardiovascular diseases comprise a range of disorders affecting the heart and blood vessels that disrupt normal blood circulation and elevate the risk of conditions such as heart attacks and strokes. The prevalence of cardiovascular diseases is increasing primarily due to unhealthy lifestyle patterns, as higher consumption of high-fat diets, lack of physical activity, and extended sedentary behavior contribute to obesity, hypertension, and increased cholesterol levels that place additional strain on the cardiovascular system. Leqvio supports the management of cardiovascular diseases by substantially reducing LDL cholesterol levels through long-acting PCSK9 inhibition, thereby limiting plaque accumulation in arteries and decreasing the risk of atherosclerotic cardiovascular events. For instance, in September 2024, according to the American College of Cardiology, a US-based nonprofit medical society, cardiovascular diseases remained the leading contributors to global disability-adjusted life years (DALYs) and mortality, with an estimated 437 million CVD-related DALYs reported worldwide in 2023 and a 16-fold variation in DALY rates across countries. During the same year, CVDs were responsible for approximately 19.2 million deaths globally, highlighting their substantial and ongoing public health burden. Therefore, the growing incidence of cardiovascular diseases is fueling the growth of the Leqvio market.

Major companies in the Leqvio market are focusing on developing advanced injectable prescription medicines, such as Label Expansion, to improve therapeutic access and facilitate early intervention. Label Expansion refers to the regulatory approval that allows an already authorized drug to be used for additional indications, patient groups, or clinical settings. For example, in July 2023, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for a label update for Leqvio (inclisiran). This update allows its use at an earlier stage for patients with elevated LDL-C and a higher risk of heart disease, in addition to diet and statin therapy. With two doses per year after the initial doses, it provides up to a 52% reduction in LDL-C and is effective for patients who can't reach their LDL-C target despite statin therapy. This update emphasizes robust safety and efficacy data supported by the VictORION clinical trial program.

Major companies operating in the leqvio market are Novartis AG.

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leqvio market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the leqvio market by increasing costs of imported rna synthesis materials, lipid nanoparticle components, sterile injectable packaging, and cold-chain logistics systems. North America and Europe are most affected due to reliance on international rna manufacturing inputs, while Asia-Pacific faces pricing pressure on specialty cardiovascular drug imports. These tariffs increase production and distribution costs, impacting pricing strategies and market access. However, they are also encouraging domestic rna manufacturing capacity expansion, regional supply chain localization, and long-term investments in advanced cardiovascular therapeutics production.

The leqvio market research report is one of a series of new reports that provides leqvio market statistics, including leqvio industry global market size, regional shares, competitors with a leqvio market share, detailed leqvio market segments, market trends and opportunities, and any further data you may need to thrive in the leqvio industry. This leqvio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leqvio is an siRNA-based therapy designed to reduce low-density lipoprotein (LDL) cholesterol by silencing the mRNA responsible for PCSK9 production in the liver. This mechanism enhances the liver's ability to clear LDL-C from the bloodstream, lowering the risk of heart attacks, strokes, and other cardiovascular events, particularly in high-risk patients.

The main formulations of Leqvio include injectable subcutaneous formulations and pre-filled syringes or auto-injectors. The subcutaneous injectable formulation is administered in a healthcare setting, providing a controlled, long-term dosage, typically every six months after an initial dose. It is used for various indications, such as treating hyperlipidemia, managing atherosclerotic cardiovascular disease (ASCVD), and addressing familial hypercholesterolemia. Leqvio is suitable for multiple patient demographics, including adults, geriatric patients, and individuals with comorbid conditions. It is distributed through several channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. Key end users include hospitals, cardiovascular clinics, specialty pharmacies, and home healthcare providers.

The leqvio market consists of sales of multi-dose vials and ready-to-use liquid vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.